Breakthrough Antibody Treatment Mitigates Allergic Reactions to Multiple Foods, NIH Trial Reveals
An interim analysis of an advanced clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) has shown that a monoclonal antibody treatment called omalizumab significantly increased the amount of multiple common foods that food-allergic children and adolescents could consume without experiencing an allergic reaction. The trial, called OUtMATCH, aims to assess the efficacy of omalizumab in reducing allergic reactions to small amounts of food allergens. The positive results have led to a recommendation to halt enrollment in the first stage of the trial, and the FDA is reviewing a supplemental biologics license application for omalizumab for food allergy based on this interim analysis.
